EP4739701A2 - Mutéines d'interleukine 12 humaine - Google Patents

Mutéines d'interleukine 12 humaine

Info

Publication number
EP4739701A2
EP4739701A2 EP24748262.3A EP24748262A EP4739701A2 EP 4739701 A2 EP4739701 A2 EP 4739701A2 EP 24748262 A EP24748262 A EP 24748262A EP 4739701 A2 EP4739701 A2 EP 4739701A2
Authority
EP
European Patent Office
Prior art keywords
amino acid
subunit
mutein
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24748262.3A
Other languages
German (de)
English (en)
Inventor
Matthias Feige
Korbinian Liebl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen In Vertretung Des Freistaats Bayern
Original Assignee
Technische Universitaet Muenchen In Vertretung Des Freistaats Bayern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen In Vertretung Des Freistaats Bayern filed Critical Technische Universitaet Muenchen In Vertretung Des Freistaats Bayern
Publication of EP4739701A2 publication Critical patent/EP4739701A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne, entre autres, i) une mutéine de la sous-unité α de l'interleukine 12 humaine (hIL-12), au moins l'un du ou des résidus d'acide aminé de ladite sous-unité α de hIL-12 choisi dans le groupe constitué par la ou les positions de séquence 70, 71, 72, 185, 187 et 189 étant muté, ii) une mutéine de la sous-unité β de hIL-12, au moins l'un du ou des résidus d'acide aminé de ladite sous-unité β de hIL-12 choisi dans le groupe constitué par la ou les positions de séquence 37, 38, 39, 67, 81, 82, 103, 106, 115, 122, 123, 216, 221, 232 et 312 est mutée, iii) une mutéine de hIL-12, comprenant une sous-unité α (p35) et une sous-unité β (p40), la sous-unité α étant une mutéine de la sous-unité α de hIL-12 selon la présente invention, et/ou la sous-unité β étant une mutéine de la sous-unité β de hIL-12 selon la présente invention, et iv) leurs utilisations.
EP24748262.3A 2023-07-07 2024-07-05 Mutéines d'interleukine 12 humaine Pending EP4739701A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23184134 2023-07-07
PCT/EP2024/068967 WO2025012105A2 (fr) 2023-07-07 2024-07-05 Mutéines d'interleukine 12 humaine

Publications (1)

Publication Number Publication Date
EP4739701A2 true EP4739701A2 (fr) 2026-05-13

Family

ID=87196222

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24748262.3A Pending EP4739701A2 (fr) 2023-07-07 2024-07-05 Mutéines d'interleukine 12 humaine

Country Status (2)

Country Link
EP (1) EP4739701A2 (fr)
WO (1) WO2025012105A2 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
IL297186A (en) * 2020-04-17 2022-12-01 Univ Leland Stanford Junior Engineered il-12 and il-23 polypeptides and uses thereof
WO2022094046A1 (fr) * 2020-10-29 2022-05-05 Proviva Therapeutics (Hong Kong) Limited Compositions d'il-12 et leurs procédés d'utilisation
US20250051413A1 (en) * 2021-01-12 2025-02-13 Askgene Pharma Inc. Chimeric molecules comprising il-12 agonist polypeptide
CA3226924A1 (fr) * 2021-07-19 2023-01-26 Regeneron Pharmaceuticals, Inc. Agonistes du recepteur de l'il12 et leurs procedes d'utilisation
WO2023023503A1 (fr) 2021-08-16 2023-02-23 Yale University Variants de l'interleukine-12 et leurs méthodes d'utilisation
WO2023043978A2 (fr) * 2021-09-17 2023-03-23 Bicara Therapeutics Inc. Protéines de fusion de l'il-12 ciblant caix et leurs méthodes d'utilisation
EP4419545A4 (fr) * 2021-10-20 2025-10-22 Synthekine Inc Cytokines fc hétérodimères et leurs utilisations
WO2023133540A1 (fr) * 2022-01-07 2023-07-13 Lyell Immunopharma, Inc. Variants de l'il-12 à affinité modifiée

Also Published As

Publication number Publication date
WO2025012105A3 (fr) 2025-03-20
WO2025012105A2 (fr) 2025-01-16

Similar Documents

Publication Publication Date Title
US12202873B2 (en) Superagonists, partial agonists and antagonists of interleukin-2
Leonard et al. Strategies to therapeutically modulate cytokine action
Monteleone et al. Characterization of IL-17A–producing cells in celiac disease mucosa
Treml et al. The BLyS family: toward a molecular understanding of B cell homeostasis
Kim et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18
Pappu et al. The interleukin‐17 cytokine family: critical players in host defence and inflammatory diseases
Habib et al. IL-21: a novel IL-2–family lymphokine that modulates B, T, and natural killer cell responses
Sims et al. The IL-1 family: regulators of immunity
Zou et al. The function of fish cytokines
CN102665754B (zh) 衍生自il-2的免疫调节多肽及其在治疗癌症和慢性感染中的用途
US20230197187A1 (en) Selective peptide antagonists
Ren et al. Interleukin-2 superkines by computational design
TW201300409A (zh) 用於治療癌症及慢性感染之具有促效劑活性之介白素－２（ｉｌ－２）衍生物多肽
Kim et al. Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein
Eisenmesser et al. Solution structure of interleukin-13 and insights into receptor engagement
Tomasovic et al. Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases: LM Tomasovic et al.
CN114901684B (zh) 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子
Rafii et al. Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR
Ming et al. De novo design of mini-binder proteins against IL-2 receptor β chain
Liebl et al. Modeling of the human interleukin 12: receptor complex allows to engineer attenuated cytokine variants
WO2025012105A2 (fr) Mutéines d'interleukine 12 humaine
Ninomiya et al. In vitro and in vivo evaluation of chemically synthesized, receptor-biased interleukin-4 and photocaged variants
Kelso Cytokines and their receptors: an overview
Expòsit et al. Geometric tuning of cytokine receptor association modulates synthetic agonist signaling
Koliesnik et al. An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR